bluebird bio, Inc.

As of March 31, 2025, bluebird bio, Inc. has 9.79M shares outstanding.

These figures are as of March 31, 2025. The price-to-sales ratio is 0.46, and the price-to-book ratio stands at -0.01.

These figures are as of March 31, 2025. The EV/Sales ratio of 1.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of March 31, 2025, bluebird bio, Inc. maintains a current ratio of 0.55, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -325.14, indicating conservative leverage, while an interest coverage ratio of -6.58 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2025. Return on assets (ROA) is negative at -43.13, reflecting losses generated across the asset base. Inventory turnover of 1.33 indicates how many times bluebird bio, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on June 2, 2025, bluebird bio, Inc.'s stock has declined approximately 72.50% over the past 52 weeks. The 50-day moving average sits at 4.42, while the 200-day moving average is 7.51.

Over the twelve months ended March 31, 2025, bluebird bio, Inc. posted a gross margin of 27.12, reflecting its pricing power and cost economics. The operating margin of -202.52 and net profit margin of -192.39 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2025. Free cash flow yield is negative at -479.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -104.53, meaning bluebird bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

bluebird bio, Inc.'s most recent stock split took place on December 13, 2024 with a 20:1 split ratio.

As of March 31, 2025, bluebird bio, Inc. has an Altman Z-Score of -25.19, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.